ANI Pharmaceuticals, Inc.

NASDAQ:ANIP

Drug Manufacturers - Specialty & Generic

Healthcare
$71.47 -1.76%

-$1.42 today

Market cap
$1.62B
Beta
0.44
P/E (TTM)
18.5
EPS (TTM)
$4.29
52W Low $62.61High $99.50

Volume 0.29M

Average 0.35M

ANIP Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

ANI Pharmaceuticals, Inc.NASDAQ: ANIP

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization dips below year-ago levels

Q1 FY2026 depreciation & amortization of $20.92M fell 8.6% year over year, behind the +17.8% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 7.5% from the prior quarter. Over 3 fiscal years it compounded at +15.3% a year.

Context

  • Depreciation & amortization amounted to 10.3% of revenue in FY2025, down 0.7 pp from a year earlier.
  • Depreciation & amortization increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -8.6% toward the trailing-twelve-month pace of +17.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$20.92M-7.5% QoQ
Last fiscal yearDec 2025
$91.42M+35.0% YoY
LTMMar 2026
$89.45M+17.8% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-8.6%——
1 year+35.0%——
3-year CAGR+15.3%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
91.42M USD
Year-over-year change
+35.0%
4-year CAGR
+17.9%

Depreciation & Amortization vs competitors

How ANIP compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +17.8% is the 5th highest of 10, against a peer median of +12.7%.
  • Depreciation & amortization amounts to 9.7% of revenue for ANIP, versus a peer median of 7.4%.
ANIP Competitors
Depreciation & Amortization for ANIP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RDYDr. Reddy's Laboratories LimitedLTM Sep 2026₹21.51B INR+12.7%+19.7%6.5%
VTRSViatris Inc.LTM Jun 2026$2.8B USD+1.6%-2.6%19.0%
BHCBausch Health Companies Inc.LTM Jun 2026$1.17B USD-5.6%-4.7%10.8%
TEVATeva Pharmaceutical Industries LimitedLTM Jun 2026$989M USD-3.3%-8.5%5.7%
COLLCollegium Pharmaceutical, Inc.LTM Mar 2026$227.86M USD+19.7%+16.7%28.6%
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 2026$194.29M USD-20.8%-2.4%6.2%
ANIPANI Pharmaceuticals, Inc.LTM Mar 2026$89.45M USD+17.8%+15.3%9.7%
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 2026$57.48M USD+44.0%+30.0%8.0%
HROWHarrow Health, Inc.LTM Mar 2026$20.35M USD+25.1%+75.1%7.6%
LFCRLifecore Biomedical, Inc.LTM Mar 2026$9.76M USD—-23.7%7.2%
EOLSEvolus, Inc.LTM Mar 2026$9.61M USD+52.7%+24.8%3.2%
Peer median (excluding ANIP) —+12.7%+7.2%7.4%

Competitors are the stored peer set for ANIP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(42.6M)(47.9M)18.78M(18.52M)78.34M
Depreciation & Amortization47.25M59.65M59.79M67.73M91.42M
Deferred Income Tax(16.75M)(15.25M)(11.74M)(21.91M)14.24M
Stock-Based Compensation10.49M14.6M20.65M29.34M37.93M
Change in Working Capital(84K)(51.3M)24.86M(11.19M)(7.12M)
Accounts Receivables(5.55M)(36.91M)3.36M(21.09M)(58.53M)
Inventory3.22M(23.63M)(5.84M)(21.29M)(5.96M)
Accounts Payables10.17M5.04M7.55M479K15.16M
Other Working Capital(7.93M)4.2M19.79M30.71M42.21M
Other Non-Cash Items5.02M8.99M6.62M18.56M(29.57M)
Operating Cash Flow3.32M(31.2M)118.96M64.02M185.23M
Capital Expenditures(23.64M)(16.46M)(18.51M)(16.95M)(34.32M)
Acquisitions (Net)(84.49M)(33K)0(401.28M)0
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities(18.43M)(6.83M)(9.64M)12.8M(20.49M)
Investing Cash Flow(105.48M)(15.74M)(18.51M)(404.72M)(34.32M)
Debt Repayment99.02M(3M)(3M)345.22M(10.16M)
Common Stock Issued69.58M080.56M013.6M
Common Stock Repurchased(890K)(1.96M)(4.99M)(10.96M)(12.21M)
Dividends Paid(190K)(1.63M)(1.63M)(1.63M)(1.16M)
Other Financing Activities2.07M1.46M(3.5M)(67.69M)(26K)
Financing Cash Flow194.6M(5.13M)67.44M264.95M(9.94M)
Effect of Forex Changes000(470K)(233K)
Net Change in Cash92.43M(52.07M)167.89M(76.23M)140.73M
Free Cash Flow(20.32M)(47.66M)100.45M47.06M150.9M

ANI Pharmaceuticals, Inc.

NASDAQ:ANIP

Intrinsic Alpha fair value

Locked

Current Price

$71.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.